Cytogenetics, FISH and Molecular Testing in Hematologic Malignancies PDF

Preface

Cytogenetics, fluorescence in situ bybridization (FISH) and molecular tests, especially polymerase chain reaction (PCR), play an important role in the management of patients with hematologic malignancies by helpig to establish the disgnosis, as well as predict prognosis, response to treatment and disease progression. ^1-48 Chromosomal and molecular abnormalities provide the most reliable criteria for classification of hemotopoietic tumors and often comprise the basis for targeted therapy. FOr example, Philadelphia chromosome (Ph), rising from t(9;22), ^BCR/ABL confirms the diagnosis of chronic myeloid leukemia firms the diagnosis of chronic myeloid leukemia (CML) while the presence of t(15;17)^PML/RARa confirms the diagnosis of acute promyelocytic leukemia (APL). Others include: t(8;21) or inv(16) in a subset of acute myeloid leukemia (aml), chromosome 14 abnormalities in T-prolymphocytic leukemia (T-PLL), iso (7q) in hepatosplenic T-Cell lymphoma, t(11;14)